AstraZeneca Submits Seroquel sNDA For Bipolar Depression Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
If approved, Seroquel would be the only agent indicated to treat both depressive and manic episodes associated with bipolar disorder.
You may also be interested in...
AstraZeneca’s Seroquel Gets FDA Nod For Bipolar Depression
Seroquel is the first drug approved for both depressive and manic episodes associated with bipolar disorder, the firm says.
AstraZeneca’s Seroquel Gets FDA Nod For Bipolar Depression
Seroquel is the first drug approved for both depressive and manic episodes associated with bipolar disorder, the firm says.
Seroquel SR NDA Submitted For Schizophrenia
AstraZeneca's once-daily sustained-release formula extends the franchise's patent protection until 2017.